Bristol-Myers Squibb Company - Diabetes Information and Treatment

Bristol-Myers expected to focus on drug research progress, approval prospects in 2Q reportDrugmaker Bristol-Myers Squibb Co. is expected to focus on a raft of recent positive research data and plans to seek approval for several drugs when it reports its second-quarter results ...

Bristol-Myers sees big jumps in 1Q sales, profit, but lowers forecast on health overhaul costsDrugmaker Bristol-Myers Squibb Co. on Thursday reported double-digit jumps in first-quarter sales and profit, beating Wall Street expectations, but it lowered its 2010 profit forecast by a nickel ...

Bristol-Myers, partner AstraZeneca get EU approval for diabetes drug Onglyza, rival for MerckDrugmaker Bristol-Myers Squibb Co. said Monday that its new diabetes drug, Onglyza, has been approved for sale in the European Union's 27 countries. That means Onglyza will compete with Merck ...

FDA clears potential blockbuster diabetes drug from drugmakers Bristol-Myers and AstraZenecaFederal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC. The Food and Drug Administration said it approved the companies' drug Onglyza to ...

A potential blockbuster diabetes medication from Bristol-Myers Squibb appears free from heart-related side effects that have plagued similar treatments, federal health officials said Monday. Despite low rates of heart attacks and related problems in testing, the Food and Drug Administration will still ...

Topic: Bristol-Myers Squibb Company

Earnings Preview: Bristol-Myers to discuss R&D

Bristol-Myers sees big jumps in 1Q sales, profit

Bristol-Myers gets EU approval for diabetes drug

FDA approves new diabetes drug Onglyza

FDA: Bristol-Myers diabetes drug appears safe

Photo Gallery

From Around the Web

Video Gallery

Follow this Topic with...